IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (1164)	7/25/1997 8:44:00 PM
From: Pseudo Biologist	of 1762

George, the Xoma -Genentech/IDEC agreement is centered on the patent assigned to Xoma patent.womplex.ibm.com It covers any chimeric antibody against the CD20 antigen (not clear if known as such at the time the "chimerization" work was done). This work was done by Xoma scientists independently of (and previously to) the work done at IDEC; too bad for Xoma they never pursued it for themselves as they were too busy fighting with Centocor over their (failed) sepsis antibody drugs. However, Xoma was smart enough to pursue the patent, and find itself in position of blocking C2B8 unless Genentech/IDEC licensed from them (which, of course, they did). I would venture that this royalty is well below 5% on revenues, probably not enough to make Xoma a "C2B8 play" Max/PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next